Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca’s pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects.

…read more

Source: AstraZeneca earmarks $200M to support its burgeoning biologics pipeline


0 No comments